Myelodysplastic syndromes, collectively called MDS, are a group of blood cancers in which the bone marrow fails to produce enough healthy blood cells. The marrow is often packed with immature or defective cells, yet the bloodstream runs short on red cells, white cells, or platelets because those abnormal cells die before they mature. MDS typically creeps in slowly, and many people are diagnosed only after routine blood work turns up unexplained low counts. The disease overwhelmingly affects older adults, though rare inherited forms can appear in children, and how it behaves varies widely from a mild, chronic condition managed with transfusions to an aggressive disease that transforms into acute leukemia.
What Goes Wrong in the Bone Marrow
MDS begins when a blood-forming stem cell in the bone marrow picks up genetic mutations that let it grow faster than its neighbors. Over time, copies of that single mutant cell crowd out normal stem cells, creating what doctors call a clonal disease. Researchers have identified more than 50 genes that are recurrently mutated in MDS, including genes involved in how cells read and process their DNA instructions and how they switch genes on or off through chemical tags on the chromosome.
The central puzzle of MDS is that the marrow is usually full of cells, yet the patient’s blood counts are low. The explanation lies in a process called ineffective blood-cell production. In early-stage MDS the abnormal cells trigger an exaggerated self-destruct signal. Inflammatory molecules ramp up inside the marrow and push developing blood cells into premature death before they can leave the marrow and enter circulation. That combination of a busy marrow and empty bloodstream is the hallmark paradox of MDS.
As MDS advances, the balance shifts. The clone accumulates additional mutations that help cells dodge those self-destruct signals, and immature blast cells begin to pile up. If blasts rise above a certain threshold in the marrow, the disease has crossed into acute myeloid leukemia, a related but more aggressive cancer.
Causes and Risk Factors
Age is by far the strongest risk factor. The median age at diagnosis is over 70, and incidence climbs steeply in every decade past 50. In people over 70, MDS is more than three times as common as acute myeloid leukemia. Because populations are aging in most high-income countries, both the number of new cases and the number of people living with MDS continue to rise.
Why age matters so much comes back to how mutations accumulate. Every time a stem cell divides, there is a small chance of a copying error. By the time a person reaches their seventies or eighties, stem cells have divided thousands of times, and the odds that one lineage has collected enough harmful mutations to become MDS go up substantially.
Prior cancer treatment is the second-best-understood trigger. Chemotherapy and radiation therapy both increase the chance of developing MDS years after the original cancer is treated. A large population-based study found that cancer patients who had received radiation or chemotherapy developed MDS at roughly one and a half times the rate of cancer patients who had not. This form, sometimes called therapy-related MDS, tends to carry a worse prognosis than MDS that arises on its own.
Chemical exposures round out the established risk factors. Benzene has the strongest evidence. A pooled analysis of petroleum workers showed a clear dose-response relationship: those with the highest cumulative benzene exposure had roughly four times the odds of developing MDS compared to those with the lowest exposure. A separate population-based study also linked benzene and vinyl chloride exposure to higher rates of both MDS and acute myeloid leukemia. Reviewers have concluded that the evidence connecting benzene to MDS is strong enough that it should factor into formal risk assessments for workers in exposed industries.
Symptoms and How MDS Is Usually Caught
MDS typically has an insidious presentation. Symptoms depend on which blood-cell lines are most affected, and many patients have no obvious complaints at all early on. The disease is often first suspected when a routine complete blood count shows one or more unexpectedly low values.
- Anemia: Low red blood cells cause fatigue, weakness, shortness of breath on exertion, and pallor. Because anemia is the most common finding in MDS, fatigue is usually the symptom that drives people to seek care.
- Low platelets: Thrombocytopenia can cause easy bruising, tiny red spots on the skin called petechiae, or prolonged bleeding from minor cuts.
- Low white cells: Neutropenia raises infection risk. Recurrent or unusually severe infections, particularly bacterial ones, may be an early clue.
Because these symptoms overlap with dozens of other conditions, MDS can go unrecognized for months or even years. Fatigue in a 70-year-old is easy to dismiss as normal aging. The challenge is distinguishing MDS from non-cancerous causes of low blood counts such as nutritional deficiencies, chronic disease, or medication side effects. Flow cytometry, a technique that identifies abnormal surface markers on blood cells, has proved valuable in this gray zone. When the bone marrow looks ambiguous under the microscope and chromosome tests are inconclusive, flow cytometry can help rule MDS in or out with high specificity.
How MDS Is Classified
MDS is not one disease but a family of related conditions, and classification systems try to sort patients into subtypes that predict behavior and guide treatment. Both the World Health Organization’s 2022 system and the International Consensus Classification divide MDS subtypes based on a combination of factors: which specific genetic or chromosomal abnormalities are present, how many blast cells appear in the marrow, and how many cell lines look abnormal under the microscope.
Some subtypes carry specific molecular signatures with direct treatment implications. MDS with a deletion on chromosome 5q, for example, responds well to the drug lenalidomide. MDS with ring sideroblasts, a subtype in which iron-loaded granules form a ring inside developing red cells, often responds to the drug luspatercept. Other subtypes are defined more by risk: how likely the disease is to progress and how long survival is expected to be without intervention.
Classification has grown more molecular over time. Earlier systems leaned heavily on how cells looked under the microscope. The newest frameworks place increasing weight on genetic sequencing, because the specific mutations a patient carries tell clinicians more about prognosis and treatment response than morphology alone.
Predicting Prognosis with Risk Scores
Not every case of MDS needs the same urgency. Risk-scoring systems help doctors and patients decide whether to watch and wait, start a low-intensity treatment, or move quickly toward aggressive therapy. The most widely used tool for years has been the Revised International Prognostic Scoring System, or IPSS-R, which combines blood counts, the percentage of blasts in the marrow, and chromosome findings to assign patients to one of several risk groups.
A newer tool, the Molecular IPSS (IPSS-M), adds genetic sequencing data from 31 genes to the mix. In a large validation study, the IPSS-M reclassified nearly half of patients into a different risk group than the IPSS-R had assigned, meaning it changed the clinical picture for a substantial share of people. The IPSS-M sorts patients into six categories, from Very Low risk with a median survival exceeding 12 years to Very High risk with a median survival under 10 months. That spread illustrates how dramatically different MDS can look from one patient to the next.
Researchers are already working to refine the IPSS-M further. One recent analysis found that incorporating whether a patient depends on regular red blood cell transfusions improves the scoring system’s accuracy, because transfusion dependence itself carries prognostic weight beyond what the genetic and cytogenetic data capture.
Treatment for Lower-Risk MDS
For patients in the lower-risk categories, the primary goal is managing symptoms and keeping blood counts high enough to avoid complications, rather than trying to cure the disease outright. Many lower-risk patients live for years with supportive care alone.
Erythropoiesis-stimulating agents, or ESAs, are the backbone of anemia treatment in lower-risk MDS. These drugs mimic a natural hormone that tells the marrow to make more red blood cells. A meta-analysis found that both major ESA drugs produce comparable response rates of roughly 58 to 59 percent when standardized selection and evaluation criteria are used. Patients who respond to ESAs tend to live longer than those who do not, and the treatment can spare many people from transfusion dependence for months or years.
Certain subtypes benefit from targeted drugs. Lenalidomide works especially well in patients whose MDS involves a deletion on chromosome 5q, sometimes eliminating the abnormal clone entirely. Luspatercept, a newer agent, is approved for patients with ring sideroblasts who have not responded to ESAs; it works through a different mechanism by blocking signals that impede late-stage red blood cell maturation. For patients with unusually low marrow cellularity, immunosuppressive therapy can sometimes restore more normal blood-cell production.
Red blood cell transfusions remain a mainstay for patients who do not respond to drug therapy or whose anemia is severe. Platelet transfusions and antibiotics address the other cytopenia-related complications. The trade-off is that chronic transfusions bring their own set of problems.
The Iron Overload Problem
Each unit of transfused red blood cells delivers a substantial dose of iron, and the human body has no efficient way to get rid of excess iron. In patients who receive transfusions regularly over months or years, iron accumulates in the liver, heart, and endocrine organs, eventually causing damage. The disease itself makes matters worse because ineffective blood-cell production causes the gut to absorb more dietary iron than normal.
Retrospective studies suggest that MDS patients with iron overload have shorter overall survival and worse outcomes if they eventually undergo a stem cell transplant, compared to similar patients without iron overload. Becoming transfusion-dependent also takes a measurable toll on quality of life. One analysis found that the transition from transfusion independence to regular transfusion dependence can cut quality-of-life scores roughly in half, depending on the measure used. Beyond the medical burden, the time commitment of frequent hospital visits for transfusions shapes daily life in ways that blood counts alone do not capture.
Iron chelation therapy, drugs that bind excess iron so the body can excrete it, is sometimes used in lower-risk patients expected to live long enough to benefit from reducing iron stores. But chelation carries its own side effects and costs, so the decision hinges on individual circumstances.
Treatment for Higher-Risk MDS
When MDS falls into the higher-risk categories, the goals shift toward slowing disease progression and extending survival. Two drugs called hypomethylating agents, azacitidine and decitabine, are the standard first-line treatment. They work by removing chemical tags that silence certain genes in the abnormal cells, allowing tumor-suppressor genes to function again. Response rates sit below 50 percent, and most patients who do respond eventually relapse, but these drugs represent a meaningful advance over older supportive-care-only approaches. One early multicenter study of decitabine in high-risk patients reported an overall response rate of 49 percent and a median survival of 15 months from the start of therapy.
Allogeneic stem cell transplant, receiving healthy marrow from a donor, remains the only treatment that can cure MDS. The problem is the patient population. Because MDS overwhelmingly strikes older adults, many patients carry other health conditions that make transplant risky. Transplant-related complications, including graft-versus-host disease and infections, cause significant illness and death, especially in older recipients. Advances in reduced-intensity conditioning regimens have expanded transplant eligibility, and one analysis at a major cancer center found that roughly 80 percent of newly diagnosed MDS patients met predefined eligibility criteria for transplant, far more than the fraction who actually receive one. The gap suggests that transplant is underutilized, partly because of physician and patient caution about the risks and partly because of donor availability and logistical barriers.
For fit patients with higher-risk disease, guidelines generally favor earlier transplant rather than waiting. Lower-risk patients may benefit from a period of watchful management before committing to a transplant, since the expected years of life gained need to outweigh the upfront danger of the procedure.
MDS in Children and Younger Adults
Although MDS is overwhelmingly a disease of aging, it does occur in children and younger adults, and the biology looks quite different. Pediatric MDS tends to present with a hypocellular marrow rather than the hypercellular marrow seen in most older patients, and the chromosome abnormalities that dominate are monosomy 7 and trisomy 8. The somatic mutations found in children’s MDS affect different genes than the ones commonly mutated in adult cases. The splicing-factor and epigenetic-regulator mutations that are hallmarks of adult MDS are virtually absent in children.
Inherited genetic predispositions play a much larger role in younger patients. Conditions like GATA2 deficiency and SAMD9/SAMD9L syndromes together account for at least 15 percent of pediatric MDS cases. Other inherited bone marrow failure syndromes, such as Fanconi anemia and Shwachman-Diamond syndrome, also carry elevated MDS risk. Recognizing these germline predispositions matters for treatment decisions and for screening family members who may carry the same variants. Because pediatric MDS is biologically distinct, treatment strategies developed for older adults do not always apply, and transplant is pursued more readily given the longer life expectancy at stake.
Newer Drugs and Ongoing Research
The treatment landscape for MDS is shifting. One of the more active areas involves targeted inhibitors for specific mutations. IDH1 inhibitors, including ivosidenib and olutasidenib, have shown promise in patients whose MDS carries IDH1 mutations. IDH2 inhibitors and FLT3 inhibitors, both already used in acute myeloid leukemia, are being investigated in MDS as well. Because MDS and AML share overlapping mutational profiles, drugs developed for one disease frequently find their way into trials for the other.
Research is also working on improving hypomethylating agent therapy. Since fewer than half of higher-risk patients respond and most responders eventually relapse, investigators have tested dozens of combination regimens pairing azacitidine or decitabine with other agents. Results so far have been mixed. Finding reliable second-line options after hypomethylating agent failure remains one of the biggest unmet needs in MDS care.
Beyond drugs, diagnostic technology continues to evolve. Next-generation sequencing panels are becoming routine in the workup of suspected MDS, and their integration into scoring systems like the IPSS-M has already changed how patients are counseled about their prognosis. As costs drop and turnaround times shorten, genetic profiling at diagnosis is likely to become universal rather than a specialty-center luxury. For a disease as heterogeneous as MDS, the trend toward treating the specific molecular subtype rather than the broad category may ultimately be the development that matters most.